Margarida Rodrigues,  —

Parkinson’s Patients with Severe Pain Benefit from Oxycodone-Naloxone Treatment

In a recent paper published in The Lancet Neurology, researchers evaluated the analgesic effect of prolonged-release oxycodone-naloxone (OXN PR) in patients with Parkinson’s disease (PD) suffering from severe and chronic pain in a pioneer Phase II clinical trial. Pain is a very common, non-motory symptom in PD patients (approximately 60% of patients)…

Cell Death in Parkinson’s Disease Associated With New Genetic Mutation

Parkinson’s disease is still the second most common neurodegenerative disorder affecting millions of people worldwide. A multidisciplinary team of researchers from UCL, the University of Cambridge and the University of Sheffield, have recently published a study in Nature Neuroscience linking a Parkinson’s disease-causing mutation in the Fbx07 gene…